Status:
UNKNOWN
Deficient T Regulatory Cell (Treg) Function in Patients With Relapsing Remitting Multiple Sclerosis
Lead Sponsor:
Thomas Jefferson University
Conditions:
Relapse Remitting Multiple Sclerosis
Eligibility:
All Genders
18-55 years
Brief Summary
The purpose of this research is to find out how the T regulatory (Treg) cells control autoimmune response in multiple sclerosis. The investigators will identify Treg molecular markers and changes in f...
Detailed Description
The study will enroll 40 RRMS patients (age 18-55, expanded disability status scale (EDSS) 0-6), and 40 age-, sex- and race-matched Healthy Controls (HCs). The study subjects will be enrolled at the T...
Eligibility Criteria
Inclusion
- Confirmed diagnosis of RRMS according to McDonald's diagnostic criteria
- Age 18-55
- Extended disability status score (EDSS) 1.5-5.5
- No immunomodulatory therapy at the time of the study. (Treatment-free period will be at least 4 weeks for IV Methylprednisolone, Interferon-beta, Glatiramer acetate, Fingolimod, Tecfidera and Natalizumab. Patients previously treated with immunosuppressive therapies, including Azathioprine, Methotrexate, Mitoxantrone and Cyclophosphamide will not be enrolled in the study.)
Exclusion
- Concomitant infection
- Significant medical and psychiatric condition at the discretion of principal investigator
- Pregnant women
- Patients participating in other research trials
Key Trial Info
Start Date :
June 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2023
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04857489
Start Date
June 1 2020
End Date
June 1 2023
Last Update
June 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107